智通财经网·2026-02-09 14:04Core Viewpoint - Novo Nordisk (NVO.US) shares rose over 4% to $49.88 following the news that competitor Hims & Hers Health (HIMS.US) has withdrawn its plans to launch a low-cost generic weight loss drug due to regulatory and legal pressures, alleviating market concerns about the impact of cheaper alternatives on Novo Nordisk's core products [1] Group 1: Market Impact - The withdrawal of Hims & Hers Health's generic weight loss drug plan significantly eases concerns regarding the competitive threat to Novo Nordisk's GLP-1 drug market [1] - Novo Nordisk's stock repurchase plan has been announced, with a maximum buyback amount of 15 billion Danish kroner [1] Group 2: Legal Actions - Novo Nordisk has filed a lawsuit in Delaware against Hims, alleging that Hims' products, including its weight loss injection, are composite forms of semaglutide, thus infringing on its patents [1] - Novo Nordisk's statement highlights that Hims has engaged in promotional activities that mislead consumers and healthcare professionals regarding the clinical efficacy and safety of its unapproved drugs [1]